Breaking News

Coherus and KBI Sign Manufacturing Pact

Relates to commercial supply of CHS-1701

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Coherus BioSciences has formed a manufacturing agreement with KBI Biopharma for long-term commercial manufacturing of CHS-1701, its pegfilgrastim (Neulasta) biosimilar candidate. KBI will manufacture and deliver production quantities of CHS-1701 for the planned commercial launch of CHS-1701 and multiple years of commercial product sales.  Coherus has recently indicated that it expects to file its CHS-1701 Biologics License Application (BLA) in the second quarter of 2016. “We believe this a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters